We previously demonstrated that perturbation of the NFκB pathway can enhance the cytotoxicity of targeted therapies against CLL cells, including that of the Bcl-2 antagonist venetoclax [28]. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.